Drug
Alogliptin clinical trials
Also written SYR-322, Nesina and SYR110322.
- studies test it
- 46
- open now
- 0
- in phase 3
- 27
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2006 (8)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 4 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 27
- Phase 4
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 6
Takeda (37) · Kun-Ho Yoon (2) · Celltrion Pharm, Inc. (1) · Sanofi (1) · AstraZeneca (1) · Fourth People's Hospital of Shenyang (1) · Seoul National University Hospital (1) · University of Catanzaro (1)
Often tested with
Tested in the same studies.
Pioglitazone (11) · Metformin (9) · Glimepiride (3) · Trelagliptin (2) · Voglibose (2) · SYR-322-4833 (1) · Roflumilast (1) · SYR-322MET (1)
Studies
Open first, then newest update. How each study uses alogliptin is read from its arms, and is right about nine times in ten.
Testing it · 46
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin TherapyCompletedPhase 4Celltrion Pharm, Inc.NCT03499704Written as Pioglitazone + Alogliptin
- Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes MellitusCompletedPhase 4TakedaNCT03231709Written as Alogliptin
- An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes MellitusCompletedPhase 4TakedaNCT02771093Written as Alogliptin
- Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male SubjectsCompletedPhase 3TakedaNCT02276274Written as SYR-322-MET
- Phase 3 Alogliptin Pediatric StudyCompletedPhase 3TakedaNCT02856113Written as Alogliptin Benzoate
- Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug NaiveCompletedPhase 4SanofiNCT03794336Written as Alogliptin
- Glimepiride, Alogliptin and Alogliptin+Pioglitazone CombinationStatus unknownPhase 4Seoul National University HospitalNCT04470310Written as Alogliptin 25Mg Tab
- Anti-inflammatory Status in DM2 Treated PatientsStatus unknownPhase 4University of CatanzaroNCT04392557Written as Metformin / alogliptin Oral Product
- A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian ParticipantsCompletedPhase 1TakedaNCT03501277Written as Alogliptin
- An Extension Study of PEAK TrialTerminatedPhase 4Kun-Ho YoonNCT02763007Written as alogliptin+pioglitazone
- The Practical Evidence of Antidiabetic Combination Therapy in KoreaCompletedPhase 4Kun-Ho YoonNCT02231021Written as alogliptin
- Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes MellitusWithdrawnPhase 4TakedaNCT03042325Written as Alogliptin
- Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 DiabetesCompletedPhase 1AstraZenecaNCT01664624Written as Alogliptin
- Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 DiabetesCompletedPhase 3TakedaNCT01890122Written as Alogliptin
- Phase 1 Bioavailability Study of SYR-322METCompletedPhase 1TakedaNCT02508168Written as Alogliptin
- The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin MonotherapyCompletedNot applicableFourth People's Hospital of ShenyangNCT02798172Written as Alogliptin and Metformin
- Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes MellitusCompletedPhase 1TakedaNCT00957268Written as Alogliptin
- Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary SyndromeCompletedPhase 3TakedaNCT00968708Written as Alogliptin
- Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 DiabetesCompletedPhase 3TakedaNCT01456130Written as Alogliptin
- Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes MellitusCompletedPhase 3TakedaNCT00856284Written as Alogliptin
See all 46 studies that test alogliptin →
Given in every arm · 2 — alogliptin is usual care beside what is tested
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminRecruitingPhase 3CelltrionNCT07093476Written as Alogliptin
- Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise TherapyCompletedPhase 3TakedaNCT02068443Written as Alogliptin
As the comparator · 5 — what is tested is compared with alogliptin
- Double-blind Comparative Study of SYR-472CompletedPhase 3TakedaNCT01632007Written as Alogliptin 25 mg
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedPhase 3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT05782192Written as Alogliptin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy VolunteersCompletedPhase 1CelltrionNCT05363592Written as Alogliptin Benzoate 12.5 mg
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy VolunteersCompletedPhase 1CelltrionNCT05363384Written as Alogliptin Benzoate 25 mg
- Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes MellitusTerminatedPhase 2TakedaNCT00763347Written as Alogliptin
Codes
What other systems call alogliptin · ClinicalTrials.gg INT005111
- MeSH (NLM) C520853alogliptinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) JHC049LO86ALOGLIPTINConfirmed FDA, NLM, Wikidata
- RxNorm 1368001Confirmed FDA, Wikidata
- Wikidata Q4734170alogliptinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76906AlogliptinOne source FDA
- DrugBank DB06203One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520853 | alogliptin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | JHC049LO86 | ALOGLIPTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1368001 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4734170 | alogliptin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76906 | Alogliptin | One source FDA |
| DrugBank | DB06203 | — | One source Wikidata |
Also registered as alogliptin benzoate (UNII EEN99869SC · RxNorm 1368000).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.